Globe Newswire06.21.18
Valeritas Holdings Inc., developer of the V-Go Wearable Insulin Delivery device, has disclosed results of a 14-month analysis that showed patients with diabetes benefited from significant and sustained reductions in A1C compared to baseline over time with V-Go use.
“Diabetes is a chronic progressive disease and managing multiple insulin injections can be a constant challenge for patients with diabetes when a basal-bolus insulin regimen is required to reach treatment goals,” said Dr. David Sutton, lead author and co-founder, Northeast Florida Endocrine and Diabetes Associates LLC, in Jacksonville, Fla. “We are encouraged to see the clinical benefits of V-Go are sustained over time.”
The current study demonstrated V-Go use was associated with improved A1C, which was sustained for over a year in 103 patients with diabetes in a real-world setting. Reductions in A1C with V-Go ranged from 1.3 percent to 1.7 percent over the course of the study. At baseline, 33 percent of patients used two or more concomitant medications and, by 14 months, this was reduced by more than half to 15 percent of patients. Therefore, the improvements in A1C seen in the study were not attributable to changes in concomitant non-insulin glucose lowering medications. Further, improvements in A1C were achieved using less insulin. Patients prescribed basal-bolus regimens with conventional insulin delivery at baseline observed a reduction in insulin of nearly 30 percent after switching to V-Go.
“V-Go provides patients a simpler and more convenient alternative to having to take multiple daily shots in order to deliver basal-bolus insulin and we are pleased to see additional evidence published supporting the benefits of V-Go for insulin delivery in patients with diabetes.” said John Timberlake, president and CEO of Valeritas.
Valeritas is a commercial-stage medical technology company that has developed the V-Go Wearable Insulin Delivery device—a simple, affordable, all-in-one basal-bolus insulin delivery option for patients with diabetes that is worn like a patch and can eliminate the need for taking multiple daily shots. V-Go administers a continuous preset basal rate of insulin over 24 hours, and it provides discreet on-demand bolus dosing at mealtimes. It is the only basal-bolus insulin delivery device on the market specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, N.J., Valeritas operates its R&D functions in Marlborough, Mass.
“Diabetes is a chronic progressive disease and managing multiple insulin injections can be a constant challenge for patients with diabetes when a basal-bolus insulin regimen is required to reach treatment goals,” said Dr. David Sutton, lead author and co-founder, Northeast Florida Endocrine and Diabetes Associates LLC, in Jacksonville, Fla. “We are encouraged to see the clinical benefits of V-Go are sustained over time.”
The current study demonstrated V-Go use was associated with improved A1C, which was sustained for over a year in 103 patients with diabetes in a real-world setting. Reductions in A1C with V-Go ranged from 1.3 percent to 1.7 percent over the course of the study. At baseline, 33 percent of patients used two or more concomitant medications and, by 14 months, this was reduced by more than half to 15 percent of patients. Therefore, the improvements in A1C seen in the study were not attributable to changes in concomitant non-insulin glucose lowering medications. Further, improvements in A1C were achieved using less insulin. Patients prescribed basal-bolus regimens with conventional insulin delivery at baseline observed a reduction in insulin of nearly 30 percent after switching to V-Go.
“V-Go provides patients a simpler and more convenient alternative to having to take multiple daily shots in order to deliver basal-bolus insulin and we are pleased to see additional evidence published supporting the benefits of V-Go for insulin delivery in patients with diabetes.” said John Timberlake, president and CEO of Valeritas.
Valeritas is a commercial-stage medical technology company that has developed the V-Go Wearable Insulin Delivery device—a simple, affordable, all-in-one basal-bolus insulin delivery option for patients with diabetes that is worn like a patch and can eliminate the need for taking multiple daily shots. V-Go administers a continuous preset basal rate of insulin over 24 hours, and it provides discreet on-demand bolus dosing at mealtimes. It is the only basal-bolus insulin delivery device on the market specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, N.J., Valeritas operates its R&D functions in Marlborough, Mass.